Julien Thery
Overview
Explore the profile of Julien Thery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srour E, Martin N, Drullion C, De Schutter C, Giroud J, Pioger A, et al.
Aging (Albany NY)
. 2024 Nov;
16(21):13201-13224.
PMID: 39560493
Aging of the epidermis partially occurs as a consequence of epidermal cell senescence, a non-proliferative state in which cells remain metabolically active and acquire changes in their secretome. We previously...
2.
Penel N, Bonvalot S, Le Deley M, Italiano A, Tlemsani C, Pannier D, et al.
Int J Cancer
. 2023 Mar;
153(2):407-416.
PMID: 36883417
The aim of this study is to evaluate the prevalence, determinants and prognostic value of pain at diagnosis in patients with desmoid-type fibromatosis (DF). We selected patients from the ALTITUDES...
3.
Bauwens E, Paree T, Meurant S, Bouriez I, Hannart C, Wera A, et al.
J Invest Dermatol
. 2022 Dec;
143(4):554-565.e9.
PMID: 36528129
Skin is one of the most exposed organs to external stress. Namely, UV rays are the most harmful stress that could induce important damage leading to skin aging and cancers....
4.
Penel N, Bonvalot S, Bimbai A, Meurgey A, Le Loarer F, Salas S, et al.
Clin Cancer Res
. 2022 Mar;
28(18):4105-4111.
PMID: 35294527
Purpose: This prospective nationwide cohort study aimed to investigate desmoid-type fibromatosis (DF) outcomes, focusing on the prognostic value of CTNNB1 mutations. Experimental Design: ALTITUDES (NCT02867033) was a nationwide prospective cohort...
5.
Regis C, Le Deley M, Bogart E, Leguillette C, Boulanger L, Chauvet M, et al.
Ann Surg Oncol
. 2021 Nov;
29(4):2652-2661.
PMID: 34839425
Background: The objective of breast reconstruction (BR) is to erase the after-effects of total mastectomy by allowing patients to restore their breast shape. The aim of our study was to...
6.
Narducci F, Bogart E, Hebert T, Gauthier T, Collinet P, Classe J, et al.
Gynecol Oncol
. 2020 May;
158(2):382-389.
PMID: 32467054
Objective: In gynecologic oncology, minimally invasive surgery using conventional laparoscopy (CL) decreases the incidence of severe morbidity compared to open surgery. In 2005, robot-assisted laparoscopy (RL) was approved for use...
7.
Vanseymortier M, Thery J, Penel N
Bull Cancer
. 2019 Mar;
106(4):389-394.
PMID: 30885366
The regulatory framework of clinical research is necessary to ensure the protection of participants and to define the actors and their responsibilities. Although main principles have been set up in...
8.
Brodowicz T, Mir O, Wallet J, Italiano A, Blay J, Bertucci F, et al.
Eur J Cancer
. 2018 Jun;
99:28-36.
PMID: 29902612
Introduction: The placebo-controlled phase-2 REGOSARC trial demonstrated the efficacy of regorafenib in patients with leiomyosarcoma, synovial sarcoma and other non-adipocytic sarcoma but not in liposarcoma. Patients initially allocated to placebo...
9.
Lawlor D, Martin P, Busschots S, Thery J, OLeary J, Hennessy B, et al.
J Pharm Sci
. 2014 Apr;
103(6):1913-20.
PMID: 24700236
The cytotoxicity of PARP inhibitors olaparib, veliparib, and CEP-8983 were investigated in two P-glycoprotein (P-gp) overexpressing drug-resistant cell models (IGROVCDDP and KB-8-5-11). IGROVCDDP and KB-8-5-11 were both resistant to olaparib...
10.
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al.
Mol Oncol
. 2013 Feb;
7(3):567-79.
PMID: 23415752
Mutations in BRCA1/2 increase the risk of developing breast and ovarian cancer. Germline BRCA1/2 mutations occur in 8.6-13.7% of unselected epithelial ovarian cancers, somatic mutations are also frequent. BRCA1/2 mutated...